![]() |
Islets of Langerhans are made of four different cell types. The majority are insulin-producing beta cells (shown in green) |
A study published in Cell last
year offered evidence that a hormone called betatrophin, or Angiopoietin-like
protein 8 (ANGPTL8), could ramp up pancreatic β cell proliferation in a
mouse model of insulin resistance. [1] The results made quite a splash; the study’s authors—led by
Doug Melton at Harvard University—even wrote that betatrophin treatment “could
augment or replace insulin injections by increasing the number of endogenous
insulin-producing cells in diabetics.” [2]
Early
this month, Melton
and his colleagues report a complex recipe that can transform either human ES
cells or iPS cells directly
into functional β cells. The breakthrough is based on more than a decade of
tenacious work in Melton’s lab. He and his colleagues have painstakingly
studied the signals that guide pancreas development, applying what they and
others have found to develop a method that turns stem cells into mature β
cells. “There’s no magic to this,” Melton says. “It’s not a discovery so much
as applied developmental biology.” The protocol “is reproducible, but it is
tedious,” Melton adds. The stem cells are grown in flasks and require five
different growth media and 11 molecular factors, from proteins to sugars, added
in precise combinations over 35 days to turn them into β cells. On the bright
side, Melton says, the technique can produce 200 million β cells in a single
500 ml flask—enough, in theory, to treat a patient. Melton says the protocol
seems to work equally well with ES and iPS cell lines. [3]
But a follow-up study
by an independent group of researchers found that the hormone is not required
for β cell function or growth. “The lack of expansion of the beta cell area
could theoretically be due to simultaneous increases in replication and
apoptosis frequencies. However, even if this were the case, it would not change
our observation that Angptl8 overexpression
did not increase beta cell area, contrary to what was reported by Yi
et al. (2013),” Viktoria Gusarova of Regeneron Pharmaceuticals and her
colleagues wrote in a Cell paper
published October 23. [2]
Melton’s group redid its experiments to see
what might have caused the discrepancy, finding the same result as Gusarova’s
team. The problem appears to have been variability in how the mice responded to
betatrophin. “Some mice respond strongly to ANGPTL8/betatrophin expression
but many do not” Melton and his colleagues wrote in a response article accompanying Gusarova’s study [2]____________________________________________________________________________________________________________
References
1 P. Yi et al: Betatrophin: A hormone that controls pancreatic B cell proliferation,
Cell 153, 747-758 (5) (2013) | doi: 10.1016/j.cell.2013.04.008
Cell 153, 747-758 (5) (2013) | doi: 10.1016/j.cell.2013.04.008
2 Diabetes 'Breakthrough' breaks up | The Scientist |27 October 2014 | ArticleTS
3 For diabetes, stem cell recipe offers new hope |Science | 9 October 2014 | ArticleSci